Diabetes mellitus is one of the most common chronic conditions globally, affecting over 500 million adults. Type 2 diabetes accounts for roughly 90% of cases and is characterized by insulin resistance and progressive beta-cell dysfunction. The pharmaceutical armamentarium for type 2 diabetes has expanded dramatically over the past two decades.

Metformin (a biguanide) has been the cornerstone of type 2 diabetes treatment for decades. It works primarily by reducing hepatic glucose production and improving insulin sensitivity in peripheral tissues. Metformin does not cause hypoglycemia when used alone, is weight-neutral or may promote modest weight loss, and has a well-established cardiovascular safety profile. Gastrointestinal side effects (nausea, diarrhea) are common initially but often resolve with slow dose titration or extended-release formulations. The rare but serious risk of lactic acidosis necessitates caution in patients with significant renal impairment.

Sulfonylureas stimulate insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels. They are effective, inexpensive, and have decades of clinical experience behind them. However, they carry a risk of hypoglycemia — especially in elderly patients or those with irregular eating patterns — and tend to cause weight gain of 1–4 kg.

Dipeptidyl peptidase-4 inhibitors enhance the incretin effect by preventing the breakdown of GLP-1 and GIP, hormones that stimulate insulin release after meals. They are weight-neutral, have a low risk of hypoglycemia, and are well-tolerated. Their blood sugar-lowering effect is moderate compared to other drug classes.

Sodium-glucose co-transporter 2 inhibitors represent one of the most important advances in diabetes pharmacotherapy. They work by blocking glucose reabsorption in the kidneys, causing excess glucose to be excreted in urine. Beyond glucose control, SGLT2 inhibitors have demonstrated significant cardiovascular and renal benefits in landmark trials (EMPA-REG OUTCOME, DAPA-HF, CREDENCE). They also promote weight loss of 2–3 kg. Risks include urinary tract infections, genital mycotic infections, and — rarely — euglycemic diabetic ketoacidosis.

GLP-1 receptor agonists mimic the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety. They achieve potent HbA1c reductions (1.0–1.8%) and significant weight loss (3–7 kg or more with semaglutide). They have proven cardiovascular benefits and are now recommended as second-line therapy after metformin, particularly for patients with established cardiovascular disease. Nausea and vomiting are common initial side effects.

Insulin remains essential for type 1 diabetes and for type 2 patients whose beta cells can no longer produce sufficient insulin. Modern insulin analogs include rapid-acting (lispro, aspart), long-acting (glargine, degludec), and premixed formulations. Insulin therapy requires careful dose adjustment and blood glucose monitoring to minimize hypoglycemia risk.

Treatment selection depends on multiple factors: HbA1c level, cardiovascular risk, kidney function, body weight, hypoglycemia risk, cost, and patient preference. Current ADA/EASD guidelines recommend metformin first, with SGLT2 inhibitors or GLP-1 agonists as preferred second agents for patients with cardiovascular or renal disease.

Contact your healthcare provider if you experience persistent blood sugar readings above 250 mg/dL, symptoms of hypoglycemia (sweating, tremor, confusion), unexplained weight loss, or signs of diabetic ketoacidosis (nausea, abdominal pain, fruity breath). Never adjust your diabetes medication without medical guidance.